Interim report May 1, 2009 - January 31, 2010
Oasmia Pharmaceutical AB (publ)
Interim report for the period May 1, 2009 - Jan 31, 2010
Positive clinical development for Oasmia
THE PERIOD IN BRIEF May 1, 2009 - Jan 31, 2010
• Net sales for the group amounted to TSEK 25 236 (70 536)
• Operating income amounted to TSEK -9 774 (6 160)
• Net income after tax amounted to TSEK -11 667 (5 997)
• Earnings per share amounted to SEK -0,33 (0,18)
• Comprehensive income amounted to TSEK -11 667 (5 997)
• The clinical development program for the pharmaceutical candidate Doxophos® Vet has begun.
• Patient enrollment in the Phase III study with Paccal Vet was completed.
THE THIRD QUARTER Nov 1, 2009 - Jan 31, 2010
• Net sales for the group amounted to TSEK 326 (10 750)
• Operating income amounted to TSEK -11 679 (-10 833)
• Net income after tax amounted to TSEK -11 688 (-11 089)
• Earnings per share amounted to SEK -0,32 (-0,33)
• Comprehensive income amounted to TSEK -11 688 (-11 089)
EVENTS AFTER CLOSING DAY
• The company revises financial goals for debt/equity ratio and liquidity reserve
• The Company credit facility was expanded
The report is available in PDF format here.
